Skip to main content
TipRanks
Go Ultimate75% OFF

Idexx Laboratories (0J8P) Share Price & Analysis

0 Followers

0J8P Stock Chart & Stats

$703.89-$1.87(-0.26%)
At close: 4:30 PM GMT
$500$600$700Aug 24Sep 8Sep 21Oct 5Oct 19Nov 2Nov 16
Day’s Range
$703.57 - $724.99
52-Week Range
$495.06 - $771.52
Previous Close
$705.76
Volume
N/A
Average Volume (3M)
388
Market Cap
$55.20B
Enterprise Value
$42.05B
Total Cash (Recent Filing)
$197.54M
Total Debt (Recent Filing)
$972.96M
Price to Earnings (P/E)
47.4
Beta
0.82
Next Earnings
Feb 08, 2027 (Est.)
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Recurring Diagnostics Growth

Recurring diagnostics revenue is supported by an expanding installed instrument base, consumable pull-through, new customer additions and higher testing utilization. This creates repeat revenue and strengthens customer retention, while 11% organic growth indicates durable demand across both U.S. and international markets.

Strong Margins And Cash Generation

High margins and strong free cash flow give IDEXX substantial capacity to fund innovation, software development, commercial expansion and acquisitions internally. Free cash flow at roughly 92% of net income also indicates that reported profitability is translating effectively into cash generation.

Platform Stickiness And Innovation

Very high customer retention and continued adoption of diagnostic imaging support IDEXX's embedded position in veterinary workflows. Its connected instruments, software and laboratory services can reinforce switching costs and encourage broader diagnostic use over multiple years.

Bears Say

Declining U.S. Clinical Visits

Lower U.S. clinic traffic can constrain near-term test volumes because diagnostic demand is partly tied to the number of veterinary consultations. Continued softness in visits or pet adoption could pressure utilization growth, even if aging pets provide some offset.

Modest Rapid Assay Growth

Rapid assays are an established part of IDEXX's diagnostic portfolio, yet their low growth signals weaker momentum than the company's recurring diagnostics and laboratory businesses. Persistently modest adoption could limit the contribution of this product category to overall expansion.

EzyVet Integration Dilution

The ezyVet acquisition adds software and AI capabilities, but integration costs, amortization and near-term dilution will weigh on reported profitability during the integration period. Execution must demonstrate that the acquired platform can eventually offset these initial financial pressures.

Idexx Laboratories News

0J8P FAQ

What was Idexx Laboratories’s price range in the past 12 months?
Idexx Laboratories lowest share price was $495.06 and its highest was $771.52 in the past 12 months.
What is Idexx Laboratories’s market cap?
Idexx Laboratories’s market cap is $55.20B.
When is Idexx Laboratories’s upcoming earnings report date?
Idexx Laboratories’s next earnings report is estimated for Feb 08, 2027 (not yet confirmed), which is in 82 days.
How were Idexx Laboratories’s earnings last quarter?
Idexx Laboratories released its earnings results on Nov 02, 2026. The company reported $4.01 earnings per share for the quarter, beating the consensus estimate of $3.726 by $0.284.
Is Idexx Laboratories overvalued?
According to Wall Street analysts Idexx Laboratories’s price is currently Undervalued.
Does Idexx Laboratories pay dividends?
Idexx Laboratories does not currently pay dividends.
What is Idexx Laboratories’s EPS estimate?
Idexx Laboratories’s EPS estimate is 3.34.
How many shares outstanding does Idexx Laboratories have?
Idexx Laboratories has 78,786,260 shares outstanding.
What happened to Idexx Laboratories’s price movement after its last earnings report?
Idexx Laboratories reported an EPS of $4.01 in its last earnings report, beating expectations of $3.726. Following the earnings report the stock price went up 22.544%.
Which hedge fund is a major shareholder of Idexx Laboratories?
Hedge funds hold Idexx Laboratories shares: the largest hedge-fund position in Idexx Laboratories is 415,800,618 shares, and hedge funds increased their holdings by 72.7K shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology